Trial Profile
Immune factors for ipilimumab colitis in patients with advanced melanoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 May 2017
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 26 May 2017 New trial record
- 09 May 2017 Results presented at the Digestive Disease Week 2017